Photoactivation holds promise for keratitis treatment
February 11th 2016The same photoactivation process used in collagen cross-linking for keratoconus can kill bacteria without the need for the oxygen responsible for the biomechanical effects, potentially pointing toward better treatments for keratitis, according to Olivier Richoz, MD, PhD.
Lifeless limbus: What's the diagnosis?
February 1st 2016Ophthalmology Times is pleased to announce Amelia Fong, MD, of Georgetown University School of Medicine, Washington, DC, as the second-place winner of the publication’s 2015 Resident Writer’s Award Program, sponsored by Allergan. Dr. Fong’s entry is featured here.
Advances for refractive laser surgery aim to boost outcomes
February 1st 2016Refractive laser platforms provide outstanding results, have reliable technology with excellent predictability and outcomes, and provide a broad range of applications. Better diagnostic imaging is possible with optical coherence tomography and Scheimpflug technology, and the advances of femtosecond lasers are moving into cataract surgery, said Michael Mrochen, PhD.
Dr. David Apple's legacy endures through laboratory
February 1st 2016Were he alive today, he would likely feel heartened by how his work has been carried on by Gerd U. Auffarth, MD, FEBO, who is now director of The David J Apple International Laboratory for Ocular Pathology at the University of Heidelberg, Germany.
How success in glaucoma innovation must come from within
January 30th 2016Companies that want to sell glaucoma products must start by building their own scientific expertise, said David E.I. Pyott, CBE, who was Allergan’s chief executive officer (CEO) and chairman of its board of directors from 1998 to 2015.